Carvedilol
Carvedilol, Coreg (carvedilol) is a small molecule pharmaceutical. Carvedilol was first approved as Coreg on 1995-09-14. It is used to treat angina pectoris, heart failure, hypertension, and myocardial infarction in the USA. The pharmaceutical is active against beta-1 adrenergic receptor and beta-2 adrenergic receptor. In addition, it is known to target ryanodine receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Carvedilol, Coreg (discontinued: Carvedilol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carvedilol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COREG | Waylis Therapeutics | N-020297 RX | 1995-09-14 | 4 products, RLD |
Carvedilol phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COREG CR | Waylis Therapeutics | N-022012 RX | 2006-10-20 | 4 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| artistry beauty balm perfecting primer spf 35 broad spectrum sunscreen | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade brule | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade buff | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade cappuccino | C200263 | 2023-10-22 |
| artistry exact fit longwearing foundation shade caramel | C200263 | 2023-10-22 |
| artistry exact fit longwearing foundation shade chablis | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade chiffon | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade cream | C200263 | 2023-10-21 |
| artistry exact fit longwearing foundation shade golden | C200263 | 2023-10-22 |
| artistry exact fit longwearing foundation shade mink | C200263 | 2023-10-21 |
Show 58 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Carvedilol Phosphate, Coreg Cr, Woodward | |||
| 8101209 | 2025-09-11 | DP | |
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AG: Alpha and beta blocking agents
— C07AG02: Carvedilol
— C07F: Beta blocking agents, other combinations
— C07FX: Beta blocking agents, other combinations
— C07FX06: Carvedilol and ivabradine
HCPCS
No data
Clinical
Clinical Trials
305 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 11 | 8 | 17 | 17 | 18 | 67 |
| Heart failure | D006333 | HP_0001635 | I50 | 3 | 3 | 12 | 25 | 16 | 58 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 5 | 8 | 19 | 33 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | 3 | 6 | 7 | 14 | 28 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | 1 | 2 | 9 | 13 | 24 |
| Fibrosis | D005355 | — | — | — | 1 | 2 | 4 | 14 | 21 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 2 | 3 | 1 | 6 | 2 | 14 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 3 | 2 | 7 | 12 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | 1 | 5 | 3 | 10 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | 1 | 6 | 1 | 9 |
Show 62 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 5 | 2 | — | 1 | 9 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | 1 | — | — | 3 |
| Leukemia | D007938 | — | C95 | 1 | 1 | 1 | — | — | 3 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | 1 | — | 2 | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | 1 | — | — | 2 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | — | 1 | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | — | 1 | 1 | — | — | 2 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
| Masked hypertension | D059468 | — | — | — | — | 1 | — | — | 1 |
Show 18 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary arterial hypertension | D000081029 | — | — | 3 | 3 | — | — | 1 | 5 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | — | — | 2 | 4 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 2 | — | — | 2 | 4 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | — | — | 2 | 3 |
| Hematologic neoplasms | D019337 | — | — | — | 2 | — | — | 1 | 3 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 2 | 3 | — | — | — | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | 2 | 3 |
| Cocaine-related disorders | D019970 | — | F14 | — | 2 | — | — | 1 | 3 |
| Secondary parkinson disease | D010302 | EFO_1001175 | G21 | — | 2 | — | — | — | 2 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | 2 | — | — | — | 2 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | 4 | 13 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 3 | — | — | — | 1 | 4 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | — | — | — | — | 2 |
| Circulating neoplastic cells | D009360 | — | — | 2 | — | — | — | — | 2 |
| Sleep deprivation | D012892 | — | F51.12 | 1 | — | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
| Heart disease risk factors | D000082742 | — | — | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
| Sleep wake disorders | D012893 | — | G47 | 1 | — | — | — | — | 1 |
| Sleep | D012890 | GO_0030431 | — | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | — | — | — | 4 | 4 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 3 | 3 |
| End stage liver disease | D058625 | EFO_1001311 | K72.1 | — | — | — | — | 3 | 3 |
| Acute-on-chronic liver failure | D065290 | — | — | — | — | — | — | 3 | 3 |
| Loneliness | D008132 | — | R45.89 | — | — | — | — | 3 | 3 |
| Drug interactions | D004347 | — | — | — | — | — | — | 2 | 2 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | — | — | 2 | 2 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 2 | 2 |
| Mental health | D008603 | EFO_0003935 | — | — | — | — | — | 2 | 2 |
Show 71 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carvedilol |
| INN | carvedilol |
| Description | Carvedilol is a member of the class of carbazoles that is an adrenergic antagonist with non-selective beta- and alpha-1 receptor blocking properties which helps in the management of congestive heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent, an alpha-adrenergic antagonist, a vasodilator agent and a cardiovascular drug. It is a member of carbazoles, a secondary alcohol and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | vasodilators (undefined group) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12 |
Identifiers
| PDB | — |
| CAS-ID | 72956-09-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL723 |
| ChEBI ID | 3441 |
| PubChem CID | 2585 |
| DrugBank | DB01136 |
| UNII ID | 0K47UL67F2 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
RYR2
RYR2
Organism
Homo sapiens
Gene name
RYR2
Gene synonyms
NCBI Gene ID
Protein name
ryanodine receptor 2
Protein synonyms
Cardiac muscle ryanodine receptor, Cardiac muscle ryanodine receptor-calcium release channel, cardiac-type ryanodine receptor, islet-type ryanodine receptor, kidney-type ryanodine receptor, ryanodine receptor 2 (cardiac), Type 2 ryanodine receptor
Uniprot ID
Mouse ortholog
Ryr2 (20191)
ryanodine receptor 2 (Q9ERN6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Carvedilol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 35,511 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,445 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use